Microsoft-Backed OpenAI Launches GPT-Rosalind AI Model For Medical Applications

MT Newswires Live04-17 17:09

Microsoft-backed (MSFT) OpenAI said Thursday it introduced a specialized artificial intelligence model named GPT-Rosalind to support biology and drug discovery research.

Early adopters using the new platform in their research operations include Amgen (AMGN), Moderna (MRNA), and Thermo Fisher Scientific (TMO), among others, the company said.

The technology is designed to accelerate early-stage scientific workflows by assisting researchers with evidence synthesis, hypothesis generation, and experimental planning, OpenAI said.

The software is currently available as a research preview for qualified domestic corporate clients only through a restricted access program, it said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment